Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles  by Phogat, S. et al.
Available online at www.sciencedirect.com
08) 72–84
www.elsevier.com/locate/yviroVirology 373 (20Analysis of the human immunodeficiency virus type 1 gp41 membrane
proximal external region arrayed on hepatitis B surface antigen particles
S. Phogat a,1, K. Svehla a, M. Tang a, A. Spadaccini b, J. Muller b,
J. Mascola a, I. Berkower b, R. Wyatt a,⁎
a Vaccine Research Center, NIAID, NIH, Bethesda, MD, USA
b Center for Biologics, FDA, Bethesda, MD, USA
Received 27 July 2007; returned to author for revision 26 September 2007; accepted 6 November 2007
Available online 26 December 2007
Abstract
Vaccine immunogens derived from the envelope glycoproteins of the human immunodeficiency virus type 1 (HIV-1) that elicit broad
neutralizing antibodies remain an elusive goal. The highly conserved 30 amino-acid membrane proximal external region (MPER) of HIV gp41
contains the hydrophobic epitopes for two rare HIV-1 broad cross-reactive neutralizing antibodies, 2F5 and 4E10. Both these antibodies possess
relatively hydrophobic HCDR3 loops and demonstrate enhanced binding to their epitopes in the context of the native gp160 precursor envelope
glycoprotein by the intimate juxtaposition of a lipid membrane. The hepatitis B surface antigen (HBsAg) S1 protein forms nanoparticles that can
be utilized both as an immunogenic array of the MPER and to provide the lipid environment needed for enhanced 2F5 and 4E10 binding. We
show that recombinant HBsAg particles with MPER (HBsAg-MPER) appended at the C-terminus of the S1 protein are recognized by 2F5 and
4E10 with high affinity compared to positioning the MPER at the N-terminus or the extracellular loop (ECL) of S1. Addition of C-terminal
hydrophobic residues derived from the HIV-1 Env transmembrane region further enhances recognition of the MPER by both 2F5 and 4E10.
Delipidation of the HBsAg-MPER particles decreases 2F5 and 4E10 binding and subsequent reconstitution with synthetic lipids restores optimal
binding. Inoculation of the particles into small animals raised cross-reactive antibodies that recognize both the MPER and HIV-1 gp160 envelope
glycoproteins expressed on the cell surface; however, no neutralizing activity could be detected. Prime:Boost immunization of the HBsAg-MPER
particles in sequence with HIVenvelope glycoprotein proteoliposomes (Env-PLs) did not raise neutralizing antibodies that could be mapped to the
MPER region. However, the Env-PLs did raise anti-Env antibodies that had the ability to neutralize selected HIV-1 isolates. The first generation
HBsAg-MPER particles represent a unique means to present HIV-1 envelope glycoprotein neutralizing determinants to the immune system.
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The human immunodeficiency virus type 1 (HIV-1) envelope
glycoproteins, gp120 and gp41 are derived from a heavily gly-
cosylated precursor protein, gp160. The exterior envelope gly-
coprotein, gp120, constitutes the receptor binding domain and
undergoes a series of entry-related conformational changes, first⁎ Corresponding author. Structural Virology Section, Vaccine Research
Center, National Institutes of Health, 40 Convent Dr., Bldg. 40, Room 4512,
Bethesda, MD 20892-3005, USA. Fax: +1 301 480 2658.
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doi:10.1016/j.virol.2007.11.005upon interaction with the primary receptor, CD4, and subse-
quently with the co-receptor, CCR5 or CXCR4 (Alkhatib et al.,
1996; Berson et al., 1996; Choe et al., 1996; Deng et al., 1996;
Doranz et al., 1996; Dragic et al., 1996; Feng et al., 1996). The
transmembrane glycoprotein, gp41, constitutes the trimerization
and membrane fusion domain that mediates virus-to-cell mem-
brane fusion and entry of the viral genetic material into target
cells. The conserved, membrane proximal external region (MPER)
of the Env gp41 ectodomain, consists of approximately 30 amino
acid proximal to the viral membrane, ending at Lys 683 (HXBc2
numbering system) immediately upstream of the transmembrane
domain. The MPER is highly conserved across various strains of
HIV-1 and selected hydrophobic residues in the MPER were
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membrane proximal heel of the HIV envelope ectodomain is
the target of two of the most broadly reactive anti-HIV-1 anti-
bodies identified to date, 2F5 and 4E10 (Muster et al., 1993;
Stiegler et al., 2001). Most attempts as immunogens to re-elicit
2F5 or 4E10-like antibodies, using variety of different contexts,
have been met with limited success (Coeffier et al., 2000; Eck-
hart et al., 1996; Ernst et al., 1998; Ho et al., 2002; Liang et al.,
1999; Muster et al., 1994; Xiao et al., 2000) and summarized in
Ofek et al. (2004). To understand the atomic-level details of 2F5
recognition, the structure of 2F5 with gp41 peptides correspond-
ing to its epitope was solved (Ofek et al., 2004). The structure
revealed that the 2F5 antibody bound to only one face of an
extended peptide in a cleft between the heavy and light chain, and
that this face was much more charged than the unbound
hydrophobic face. We observed that the hydrophobic residues
at the tip of the 2F5 CDR3 loop directly adjacent to the pep-
tide comprised a contiguous hydrophobic surface. Modeling
of the 2F5-bound 17-mer peptide in the context of the virus and
surrounding gp41 sequences suggested an antibody–antigen
interaction proximal to the viral membrane. To confirm the in-
volvement of lipid in 2F5 antibody-epitope recognition, we car-
ried out a biochemical analysis with solid phase Env-containing
proteoliposomes either possessing or lacking a reconstituted
membrane. The binding of 2F5 as well as that of another mem-
brane proximal binding antibody, 4E10, could be enhanced al-
most two orders of magnitude by the presence of lipid membrane.
The solved structure of 4E10 bound to its epitope revealed helical
nature of the epitope to which 4E10 binds and implicated lipid
proximity of both antibody and antigen (Brunel et al., 2006;
Cardoso et al., 2005). These structural and biochemical studies
suggested that conformational restriction, steric occlusion of the
antibody unbound faces of the epitope and the inclusion of the
lipid in the immunogen should be considered in designing immu-
nogens with the potential to elicit 2F5- and 4E10-like antibodies
(Ofek et al., 2004; and reviewed in Phogat and Wyatt, 2007;
Phogat et al., 2007).
Viral B cell epitopes that are presented in rigid, highly
repetitive, paracrystalline form were shown to induce neutraliz-
ing antibodies that help to clear virus (Zinkernagel et al., 1996).
Furthermore, the arrayed B cell epitopes were recognized as
foreign and induced strong B cell activation to produce protec-
tive neutralizing antibodies against surface antigens in several
pathogenic viral models (Bachmann et al., 1997; Bachmann and
Zinkernagel, 1997; Zinkernagel et al., 2001). Historically, viral
vaccines have been live-attenuated or chemically inactivated
forms of the virus. The exceptions to these traditional vaccines
are few: the particulate hepatitis B virus (HBV) vaccine and
the similarly particulate human papilloma virus (HPV) vaccine
(Brown et al., 2004; Fife et al., 2004; Frazer, 2004; Koutsky
et al., 2002) but hopefully recombinant, protein-based vaccines
will increase in number. Such vaccines are generally considered
safer and less expensive for large-scale manufacture (Pantaleo
and Koup, 2004; Plotkin, 2003). The vaccine against HBV
makes use of particle-forming hepatitis B surface antigen pro-
tein, S1, and for HPV, the L1 protein. Both of these proteins self-
assemble to form viral-like particles (VLPs). Initially, theHBV surface antigen particles contain plasma-membrane-
derived lipid constituents that surround the membrane-spanning
HBsAg proteins. Assembly of viral antigens into polyvalent
VLPs, rather than as free antigens, enhanced the vaccine potency
up to 1000-fold for the HBsAg (Cabral et al., 1978; Kirnbauer
et al., 1992) and glycoprotein G of rabies vaccine (Piza et al.,
2002). The HBV and HPV VLPs were shown to be recognized
by dendritic cells (DCs), traffic intracellularly and to induce
neutralizing antibodies and CD4+/CD8+ T cell activation in a
manner comparable to native virions (Frazer, 2004; Lowe et al.,
1997; Schirmbeck et al., 1996).
Previously, recombinant HBsAg particles containing HIV
gp120 envelope glycoproteins fused with the S1 protein and the
malarial vaccine RTS,S were studied as potential vaccine can-
didates (Berkower et al., 2004; Heppner et al., 2005). The RTS,
S malarial vaccine is in clinical trials and recently was shown
to be protective against experimental challenge with Plasmo-
dium falciparum sporozoite (Stoute et al., 1997). Here we have
investigated the use of the immunogenic HBsAg particulate
platform to array the conserved, neutralization-sensitive MPER
region of HIV-1.
Results
Design of the HBsAg-MPER fusion constructs
Previous structural and biochemical studies suggested that to
elicit 2F5- and 4E10-like antibodies, the membrane context of
the respective epitopes was a critical element to be incorporated
into immunogen design. And, since peptide or antigenic arrays
were shown to enhance B cell responses, we sought to express
the MPER “miniproteins” in a hepatitis B surface antigen S1
protein particulate format (Fig. 1). Although not crystallized, the
predicted secondary structure of the S1 protein is shown as a
model in Fig. 1. The S1 protein monomers spontaneously as-
sociate into cysteine-linked dimers and eventually to highly
cysteine-crosslinked, lipid-containing nanoparticles approxi-
mately 22 nm in diameter as determined by electron microscopy
(Berkower et al., 2004; Mangold et al., 1997; McAleer et al.,
1984; see Fig. 1 for approximate positions of the intermolecular
cysteine residues). Previously, the multi-array, lipid-containing
HepB surface antigen platform has demonstrated enhanced im-
munogenicity and protective responses when presented as a
fusion protein with sequences derived from a malarial protein
(Heppner et al., 2005).
The first sets of constructs (Figs. 1 and 2A) were designed to
append the MPER to the S1 proteins at three distinct positions:
the C-terminus, the N-terminus and the immunodominant ECL
region. We chose each of these positions as they were exposed
but relatively close to the membrane bilayer and each might
enhance presentation ofMPER elements for different reasons. In
the context of the HIV-1 envelope glycoprotein, the 4E10
epitope lies proximal to the TM, which is more analogous to the
N-terminal positioning. In the ECL, we reasoned that since this
region is immunodominant it is likely well exposed and there-
fore the MPER might be better presented in this context. Po-
sitioning the MPER at the C-terminus would constrain the 2F5
Fig. 1. Schematic representation of the HIV-1 gp41, the MPER, the hepatitis B S1 protein and the HBsAg-MPER recombinant particles. The top bar diagram displays
the overall organization of the HIV-1 gp41 transmembrane glycoprotein, which contains the MPER between amino acids 656 to 683 (fusion peptide (fp); N-heptad
(heptad repeat 1); SS (cysteine-linked immunodominant region); C-heptad (heptad repeat 2); transmembrane region (tm)). In expanded section below, the MPER
residues are shown. The residues in contact with 2F5 or 4E10 in the crystal structures are “boxed” in red or purple respectively and the core residues defined in the
original peptide mapping of the epitopes are italicized (Cardoso et al., 2005; Ofek et al., 2004). From the crystal structures of peptide with antibody, the 2F5 peptide is
depicted as an extended loop (in red) and the 4E10 epitope as an alpha helix (in purple; Cardoso et al., 2005; Ofek et al., 2004). In the next panel, the MPER is
schematically shown fused to either the N- or C-terminus of the hepatitis B surface antigen S1 membrane-spanning protein as indicated by the 1/2 arrowheads. The S1
protein is in blue and the predicted alpha helices and beta strands are shown (from Mahoney and Kane, 1999). The center full arrowhead indicates the approximate
position where the MPER was inserted into the S1 extracellular loop. An “SS” marks the approximate positions of the five S1 protein cysteine residues involved in
intermolecular dimerization and oligomeric particle formation. The black asterisk indicates where additional hydrophobic C-terminal residues were added to the
MPER in selected constructs. Directly below is a schematic diagram of an HBsAg-MPER particle containing an array of an (theoretical) 180 S1-C-terminal MPER
fusion sequences per particle (not to scale).
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orientation in gp160. However, at the C-terminus the 4E10
epitope region would remain free of anchorage by the hydro-phobic TM residues found in its natural gp160 context. There-
fore, we added HIV-1 gp160 transmembrane region sequences
of varying length (5, 10, 15, or 22 amino acids) to the C-terminus
Fig. 2. Schematic representation of the construct design using the hepatitis B surface antigen S1 protein as a carrier molecule. (A) The MPER was appended at the
N-terminus, C-terminus and the immunodominant extracellular loop of the HepB S1 gene; (B) different lengths of the hydrophobic HIV-1 transmembrane region were
cloned at the C-terminus ofMPER to potentially enhance 4E10 recognition; (C) the portion of the gp41 extracellular domain beginning just after the gp41 second heptad
repeat through the MPER ending at the lysine residue at position 683 was appended at the C-terminus of the S1 protein; additionally we attempted to oligomerize the
MPER by appending a foldon trimerization motif as shown.
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4E10 epitope configuration. In other instances, to better mimic
possible but unknown natural environs of the MPER in the
functional spike, gp41 sequences upstream of the 2F5 epitope
were included and for another subset of constructs we added a
trimerization motif derived from T4 bacteriophage (foldon), in
an attempt to present the MPER region as a trimer on the HBsAg
particles (see Fig. 2C).
Partial purification of the recombinant HBsAg-MPER variants
To assess particle production of the designed HBsAg-MPER
fusion constructs, individual plasmids were transfected into
HEK293 cells. Following expression of the S1 or S1-MPER
proteins, cell supernatants were harvested and, in parallel, the
cells were treated with lysis buffer to determine the best source
for isolation of the HBsAg particles. To detect the presence of
recombinant particles, either concentrated cell supernatants or
cell lysates were fractionated by sucrose density gradient cen-
trifugation and analyzed by ELISA (before and after sucrose
density fractionation) with the HBsAg-specific antibodies. The
HIV-1 Gag particles were used as a negative control for anti-
body and epitope specificity. The presence of the MPER in theparticles was confirmed using the 2F5 antibody (Fig. 3A). By
this analysis, most constructs generated particles with the ex-
ception of those containing the C-terminal C9 tag, heptad se-
quences N-terminal to the MPER and the C-terminal foldon
sequences. Further analysis of the HBsAg particles containing
the MPER at either the N- or C-terminus was done by Western
blotting and recognition of the particles by both 2F5 and anti-
sera specific for the HBsAg S1 protein confirmed that MPER
sequences were present in the particles (Fig. 3B). When pro-
duced from the mammalian cells, the S1-MPER proteins ap-
peared as an approximate 27-kDa doublet; the two bands likely
are due to differences in glycosylation. The purified yeast-
produced HBsAg standard migrated as a 24-kDa monomer and
displayed a faint dimer band and high-order oligomers (Fig. 3B
and not shown).
Following determination that the HBsAg C-MPER protein
formed particles, the C-MPER particles were visualized by
electron microscopy to see whether they form small ∼22-nm
particles similar to the HBsAg particles. The HEK293 cells
transfected with C-MPER construct were negatively stained and
electron micrographs showed the presence of small spherical
particles that predominantly accumulate in the rough endoplas-
mic reticulum (Fig. 3C).
Fig. 3. Antigenic, biochemical and EM analysis of the variant HepB-MPER
expression constructs. (A) Shown in tabular +/- format is the ELISA analysis of
the cell lysates/supernatants derived from the expression constructs (first
column) for recognition by the HBsAg antibody (second column). In the next
two columns are ELISA results following sucrose pelleting of lysate for 2F5 to
determine if particles were detected in the pellets (third column). HIV Gag
particles and HBsAg commercially available particles were used as controls. (B)
The partially purified HepB-MPER particles were resolved side-by-side with
commercial yeast-purified HBsAg particles on SDS gels followed by Western
blotting. As shown by Western (left), the yeast particles displayed a band at
24 kDa, the mammalian-expressed HepB-MPER particles show a ~27-kDa
band and a slightly higher glycosylated form. The HBsAg C-MPER and N-
MPER particles were recognized by 2F5 but not the HBsAg particles and all
three particle types were recognized by the HBsAg antibody. (C) EM analysis of
cells transfected with HbsAg-MPER DNA showed that the predominant
compartment for accumulation of the MPER particles was in the rough
endoplasmic reticulum.
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HBsAg-MPER variants
To evaluate the positioning of the MPER sequences in the
context of S1 protein, S1-MPER particles containing the MPER
at either the N- or C-terminus of HBsAg or at the tip of the
extracellular loop (ECL) of the S1 protein were generated. The
MPER sequences placed either at the N-terminus or the ECL of
HBsAg were not well recognized by either 2F5 or 4E10
antibody, perhaps indicating that the MPER was not proximal to
the lipid bilayer. When the MPER sequences were placed at the
C-terminus, however, a strikingly different recognition pattern
of the isolated HBsAg-MPER particles by both 2F5 and 4E10
antibodies was observed (Fig. 4A, C-MPER). We interpret the
dramatic increase in recognition of the C-MPER particles
relative to the N-MPER or ECL-MPER particles by both 2F5
and 4E10 to indicate a much higher affinity for their cognate
epitopes in this context. Because the 4E10 binding to the C-
MPER particles was slightly less than that compared to 2F5,
different lengths of sequences derived from the HIV-1 TM
region (5, 10, 15 and 22-C9) were inserted at the C-terminus of
the C-MPER construct. The rationale was to potentially enhance
4E10 recognition if the hydrophobic TM-derived residues might
insert into the lipid bilayer. Appending the 15 hydrophobic
residues from the TM increasing after the C-MPER (C-MPER+
15) had the greatest impact on recognition by both the 2F5 and
4E10 antibodies (Fig. 4B). Lesser increases in 2F5 and 4E10
recognition were observed by the addition of 5 and 10 residues
from the hydrophobic TM region (not shown).
Following the observation that the C-terminal positioning of
the MPER formed particles (C-MPER) and that they were well
recognized by 2F5 and 4E10, we generated recombinant
baculovirus for large-scale production of particles in Hi5 cells.
Following expression and sucrose density gradient centrifugation,
the partially purified HepB particles were subjected further to
CsCl density fractionation. The density of the C-MPER particles
on the cesium chloride density gradient was 1.18, which is similar
to the density of 1.2 reported previously for the wild-type HBsAg
particles (Berkower et al., 2004). A representative gradient ana-
lysis is shown in Fig. 5A. This material was relatively homo-
geneous by SDS gels and was used for subsequent delipidation
and immunogenicity experiments. Following additional hydro-
phobic interaction chromatography, SDS gel analysis followed by
Coomassie blue staining showed a major single protein species
migrating at approximately 27 kDa (Fig. 5B).
Delipidation and lipid reconstitution of the HBsAg-MPER
particles to determine effects on 2F5 and 4E10 recognition
The yeast-expressed HBsAg particles used in the current
vaccine are subjected to series of drastic changes in pH (cycles
of low and high) and treated with detergent during the puri-
fication process to remove lipids and other cellular components.
Therefore, we tested if a similar process would affect 2F5/4E10
recognition. As expected from our previous analysis of the 2F5/
4E10 binding in the context of proteoliposomes (Ofek et al.,
2004), delipidation reduces the binding of the two antibodies to
Fig. 5. Analysis of the HepB-MPER particles by density gradient centrifugation
and gel electrophoresis. (A) A CsCl density gradient of the HBsAg-MPER
particles. Gradient fractions were collected and analyzed for the presence of the
MPER by ELISA. The MPER particles displayed a density of 1.18 which was
very close to the density of 1.2 displayed by the HepB particles. (B) An SDS gel
of the commercial HBsAg particles compared to the sucrose pelleted, CsCl
banded, and reverse-phase-purified C-MPER particles.
Fig. 4. Binding of 2F5 and 4E10 to HBsAg-MPER variants by ELISA. (A) The binding of 2F5 and 4E10 to HBsAg-MPER particles containing MPER sequences
at the N-terminus (N-MPER), the C-terminus (C-MPER) and the extracellular loop (ECL-MPER). Panel B shows binding of 2F5, 4E10 to C-MPER particles
compared to those containing an additional 15 hydrophobic, C-terminal residues derived from the HIV-1 transmembrane region that lies immediately proximal to the
MPER.
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reconstitution would restore recognition of 2F5/4E10 to the
MPER particles. Both 2F5 (Fig. 6, left) and 4E10 antibodies
bound with high relative affinity to the baculovirus-purified
HBsAg-C-MPER particles and removal of lipids significantly
decreased the binding of these antibodies. On reconstitution
using the synthetic lipids, DOPC:DOPS (7:3), the binding was
fully restored (Fig. 6), confirming that both 2F5 and 4E10
binding is enhanced by the presence of lipids. However, recog-
nition by these antibodies is not dependent upon native mem-
brane lipids as reconstituted synthetic lipid bilayers nearly fully
restored recognition by both antibodies, consistent with pre-
vious observations (Ofek et al., 2004). These data suggest that it
will be feasible to make large quantities of the particles in ba-
culovirus systems or in yeast. The particles can then be purified
free of cellular components and then reconstituted with syn-
thetic lipids to present the MPER for optimal recognition by
both the 2F5 and 4E10 antibodies.
HBsAg C-MPER particles raise antibodies that bind to MPER
and to HIV-1 envelope glycoproteins
Female Balb/C mice were immunized by the intramuscular
route, at intervals of 3 weeks with HBsAg, HBsAg C-MPER
particles or plasmid DNAs expressing these proteins. All the
immunogens raised significant endpoint titer antibodies against
the commercially available yeast HBsAg particles as determined
by ELISA. Endpoint titers of 1:50,000 were observed for mice
immunized with HBsAg-purified particles or HBsAg DNA,
1:15,000 for HBsAg C-MPER particles or C-MPER encodingplasmid DNA. In parallel, ELISA analysis of the sera for recog-
nition of peptides containing the 2F5 or 4E10 epitopes showed
that after four or five inoculations did sera from HBsAg-MPER-
Fig. 6. ELISA binding of 2F5 and 4E10 to HepB MPER particles before and after delipidation and following lipid reconstitution. Left, the binding of 2F5 to
unmodified HepB-MPER particles (closed squares), to HepB-MPER particles depleted of lipids (open squares) and to HepB-MPER particles possessing a
reconstituted synthetic lipid bilayer (solid triangles). Right, the binding of 4E10 to the particle preps is shown.
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Relatively low titers of 1:1000 were observed. Similarly, three
DNA inoculations followed by two boosts with the HBsAg-
MPER particles elicited high-titer antibodies directed toward the
HBsAg and low-titer antibodies against the MPER constructs.
Sera from mice inoculated four times with the HBsAg C-MPER
particles were further analyzed for binding to the MPER ex-
pressed on the cell surface by FACS. The sera displayed an end
titer similar to that observed by peptide ELISA (Fig. 7, left).
Importantly, the same sera elicited by the C-MPER showed
cross-reactivity to the primary envelope HIV envelope glyco-
proteins JR-FL, YU2 and ADA expressed on the cell surface
with roughly equivalent end titers (Fig. 7, right and not shown).
The binding of the mice sera to the MPER and HIV Env on the
cell surface was at least equivalent to the binding seen with 2F5
to these molecules (data not shown).
In a preliminary analysis, there was no detectable neutraliz-
ing activity in the mouse sera, but due to both limits of available
sera and non-specific affects of mouse sera on HIV entry, im-
munogenicity analysis of the particles was performed in rabbits.
Based upon the ability of HBsAg-MPER particles to elicit
cross-reactive antibodies to the HIV-1 Env, we used the particles
by themselves and in prime-boost regimens with native ADAFig. 7. FACS-based binding analysis of mouse anti-sera elicited by HBsAg and HBs
surface of HEK 293 cells; Right, right panel, binding of the same anti-sera to either c
shown) expressed on the cell surface. Similar patterns of binding were obtained forgp160 presented on proteoliposomes (ADA Env-PLs; Grundner
et al., 2002) in rabbits to evaluate the ability of these novel
reagents to elicit neutralizing antibodies.
Prime:Boost immunization with the HBsAg-MPER particles
and ADA Env-PLs in rabbits
The immunization protocol consisted of two priming ino-
culations followed by subsequent boosting inoculations at weeks
8 and 12 following the second “prime” (Table 1). We tested the
hypothesis that by priming:boosting with immunogens that
shared in common the MPER only, we might better focus the
antibody response to this region and thereby increase MPER-
directed neutralizing antibodies. As can be seen in Table 1, we
tested priming:boosting in both directions and included appro-
priate controls. After the 4th inoculation, sera were collected 7 to
10 days post-injection and were assessed for binding to gp120,
HBsAg particles and to MPER peptides by ELISA and sub-
sequently for HIV-1 neutralizing reactivity. All rabbits in groups
immunized with envelope containing proteoliposomes (ADA
EnvPLs) had high endpoint titer anti-gp120 antibodies (reci-
procal dilutions N105). Animal groups immunized with either
wild-type or recombinant HBsAg particles had high anti-HepBAg-MPER particles. Left, left panel, binding to the MPER expressed on the cell
leavage-competent JR-FL gp160 (+) or cleavage-defective JR-FL gp160 (−; not
YU2 gp160 expressed on the cell surface (not shown).
Table 1
Immunogenicity with selected immunogens and elicited neutralization activity against selected pseudotyped HIV-1 isolates a
Group Immunogen b prime
weeks 0, 4
Immunogen boost
weeks 8, 12
Rabbit
IDs
HXBc2 SF162 MN MW965
Post 2 Post 4 Post 2 Post 4 Post 2 Post 4 Post 2 Post 4
IC50
I Blank beads c Blank beads 1 b5 b5 b5 b5 b5 b5 b5 b5
2 b5 b5 b5 b5 b5 b5 b5 b5
II HBsAg particles HBsAg particles 3 b5 b5 b5 b5 b5 b5 b5 b5
4 b5 b5 b5 b5 b5 b5 b5 b5
III HBsAg particles ADA Env-PLs 5 b5 b5 b5 b5 b5 b5 b5 b5
6 b5 b5 b5 b5 b5 b5 b5 b5
IV HBsAg MPER particles HBsAg MEPR particles 7 b5 b5 b5 b5 b5 b5 b5 b5
8 b5 b5 b5 b5 b5 b5 b5 b5
9 b5 b5 b5 b5 b5 b5 b5 b5
10 b5 b5 b5 b5 b5 b5 b5 b5
V HBsAg MPER particles ADA Env-PLs 11 b5 b5 b5 b5 b5 b5 b5 49
12 b5 b5 b5 35 b5 1428 b5 449
13 b5 b5 b5 b5 b5 6 b5 16
14 b5 b5 b5 b5 b5 b5 b5 45
VI ADA Evn-PLs HBsAg MPER particles 15 b5 b5 b5 b5 b5 20 b5 b5
16 b5 b5 b5 b5 b5 b5 13 b5
17 b5 b5 b5 b5 b5 b5 b5 b5
18 b5 b5 b5 b5 b5 b5 b5 b5
VII ADA Env-PLs HBsAg particles 19 b5 b5 16 b5 b5 b5 112 b5
20 b5 b5 30 b5 b5 b5 166 154
VIII ADA Env-PLs ADA Env-PLs 21 b5 11 b5 18 b5 3310 b5 345
22 b5 b5 b5 b5 b5 9 100 269
23 b5 b5 18 432 b5 4107 99 886
24 b5 b5 b5 b5 b5 3597 b5 346
25 b5 b5 b5 58 1631 1809 74 841
26 116 1485 418 513 520 818 258 470
IX HBsAg MPER—20 particle ADA Env-PLs 27 b5 b5 b5 b5 b5 391 b5 137
28 b5 b5 b5 b5 b5 b5 b5 b5
29 b5 b5 b5 59 b5 30821 b5 85
30 b5 b5 b5 b5 b5 b5 b5 28
X HBsAg MPR—20 particles HBsAg MPER—20 particles 31 b5 b5 b5 b5 b5 b5 b5 b5
32 b5 b5 b5 b5 b5 b5 b5 b5
33 b5 b5 b5 b5 b5 b5 b5 b5
34 b5 b5 b5 b5 b5 b5 b5 b5
35 b5 b5 b5 b5 b5 b5 b5 b5
36 b5 b5 b5 b5 b5 b5 b5 b5
a Shown are neutralization titers from a single-round neutralization assay with sera after the second and fourth inoculations against the indicated isolates. The values
represent reciprocal serum dilutions to achieve 50% (IC50) neutralization.
b All immunogens were combined with CpG+Alum as described in the Materials and methods.
c The immunogens of blank beads and unmodified hepatitis B surface antigen particles (HBsAg) were used as negative controls for either prime or boost as
indicated.
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point titers against the MPER were relatively low (reciprocal
dilutions of 1000 to 3000).
To assess the neutralizing activity in the sera, the preimmune
and immune sera obtained post 2nd and 4th immunization were
diluted and tested in a single-round “TZM” neutralization assay
(Mascola et al., 2002; Shu et al., 2007) against the clade B
molecular clones HXBc2, SF162,MN and the clade Cmolecular
clone, MW965 (Table 1). The sera were tested to determine the
titer that resulted in 50% neutralization (IC50; Table 1) or 80%
neutralization (IC80; not shown). Neutralization was only ob-
served when the rabbits were immunized with ADA Env-PL
either as a prime or a boost; we did not observe any neutralization
with the recombinant HBsAg particles, or MPER-HBsAg par-
ticles either alone or as a prime or a boost. The anti-Env an-
tibodies showed significant neutralization of the relativelyneutralization-sensitive MN and MW965 pseudoviruses and in
some cases, neutralization of HXBc2. Mapping studies were
performed using selected neutralizing sera pre-incubated with
peptides capable of inhibiting V3-directed neutralization as
previously described (Dey et al., 2007; Li et al., 2006) or MPER-
directed neutralization (Li et al., in preparation). While there was
an indication of some V3-directed neutralization activity in
some of the Env-PL elicited sera, we could not detect the pre-
sence of any anti-MPER neutralizing antibodies as defined
by the MPER peptide inhibition assay using the HXBc2 isolate
(not shown).
Discussion
Most attempts to elicit MPER-directed neutralizing anti-
bodies have failed completely or met with limited success at
80 S. Phogat et al. / Virology 373 (2008) 72–84eliciting broadly neutralizing antibodies (summarized in Ofek
et al., 2004). Here we present a rational design of immunogens
to present the MPER on the particulate hepatitis B surface
antigen platform that has been used successfully to elicit pro-
tective antibodies against hepatitis B infection. The hepatitis B
22 nm particles form spontaneously from the multi-spanning
hepatitis S1 protein. We present data regarding several HBsAg
S1-MPER fusion constructs, their ability to form particles,
recognition of the particles by the MPER-specific antibodies
2F5 and 4E10, the effect of lipid on recognition by these
antibodies and an initial immunogenicity analysis of sera from
mice and rabbits immunized with selected HBsAg-MPER
constructs. We show that the recombinant HBsAg particles with
the MPER appended at the C-terminus of the S1 protein bind
2F5 and 4E10 with the highest affinity compared to the
positioning of MPER at N-terminus or the extracellular loop of
S1. Positioning the MPER at the C-terminus of the S1 protein
may provide proximity or an orientation to the membrane to
enhance antibody recognition compared to positions at either
the N-terminus or the ECL. Alternatively, coupling of the
MPER to the S1 protein at these two positions may occlude
antibody recognition in some unanticipated manner not
predicted by modeled secondary structure of the S1 protein
(see Fig. 1). The 2F5 epitope is in close proximity to the
membrane in C-MPER construct but on the native gp160 or
gp120/gp41 Env, the 4E10 epitope is immediately upstream of
the membrane. In a rational attempt to further improve 4E10
binding in the C-MPER particles, we appended hydrophobic
residues from the HIV-1 Env transmembrane to the C-terminal
region of the C-MPER. Addition of the hydrophobic TM
residues improved relative binding affinity of both the 2F5 and
4E10 antibodies, presumably due the presence of hydrophobic
context immediately following the hydrophobic 4E10 epitope.
Perhaps the additional hydrophobic residues permit a more
intimate association of the epitope with the lipid bilayer. This is
consistent with previous data presenting HIV gp160 in a
proteoliposome context (Ofek et al., 2004) as well as delipida-
tion/reconstitution experiments presented here.
The data suggest that specific cellular lipids were not re-
quired for binding, rather a hydrophobic context was needed, as
described for 2F5 and 4E10 binding on the proteoliposome
(Ofek et al., 2004). This further suggests that these particles can
be made in yeast following similar processes used for the HepB
vaccine, and at a final step, a lipid bilayer can be reconstituted
using synthetic lipids.
In this study, we describe our initial attempts to test the hy-
pothesis that MPER arrayed on HBsAg particles will enhance
immunogenicity of this relatively hydrophobic and membrane
proximal region. To this end, we have immunized mice with
C-terminal MPER HBsAg particles and observed that rela-
tively low titer MPER-directed antibodies were elicited. Al-
though the relatively low titer was disappointing, perhaps this
result is not so surprising given that the two immunodominant
and relatively well-exposed HepB-specific epitopes are pre-
sent in the particles. Future studies deleting these regions or
masking them with N-linked glycans may improve the relative
immunogenicity of this region.Encouragingly and importantly, the HBsAg C-MPER
particles elicited sera that showed cross-reactive binding to a
primary isolate-derived HIV-1 envelope glycoprotein expressed
on the cell surface. We feel that this is a substantial improve-
ment over other presentations of the MPER. For example, when
we coupled a peptide containing the structurally defined 2F5
epitope to KLH and immunized rabbits, we did elicit antibodies
that could recognize the free peptide but not antibodies capable
of cross recognition of native, cell surface gp160 (not shown).
This suggests that the MPER in the particle format presents
itself in a qualitatively different form than the free peptide,
although in this format both the non-neutralizing and neutraliz-
ing faces of the 2F5 and 4E10 epitopes might be accessible to
the immune system. The data do, in part, alleviate some con-
cerns that the MPER region is not immunogenic due to mimicry
of self-structures such as cardiolipin (Haynes et al., 2005) but do
not rule this out as a potential immune dampening mechanism.
It is possible that cloaking of the MPER in self-lipid renders it
poorly immunogenic or poorly accessible on the virus to most
MPER-directed antibodies. The elicitation of antibodies di-
rected toward the MPER may require the utilization of selected
MPER constructs in concert with native gp160 trimers in a
heterologous prime:boost strategy to immuno-focus the hu-
moral antibody response on relevant MPER conformations as
suggested previously (Ofek et al., 2004). As an initial test of this
hypothesis, we performed prime:boost immunization in rabbits
using both the HBsAg-MPR and Env-PL immunogens. As
shown in Table 1, we observed neutralization only when the
Env-PLs were one component of the immunization regimen.
Also the most potent neutralization was observed when the Env-
PLs were immunized four times consecutively (Group VIII
animals). Since we observed less potent immunization when the
MPER-HBsAg particles were a component of the regimen, the
data indicate that the prime:boost strategy did not preferentially
elicit MPER-directed neutralizing antibodies. As previously
reported, the Env-PLs raised anti-Env antibodies that had the
ability to neutralize some HIV isolates (Grundner et al., 2002),
but no neutralization directed toward the MPER could be de-
tected. Likely the neutralization elicited here by the Env-PLs is
also gp120 directed and not against the MPER, consistent with
the inability of peptides from this region to inhibit neutralization
of the HXBc2 isolate (not shown). The data again emphasize
that the MPER region is weakly immunogenic relative to ele-
ments of gp120 and that presentation of the correct MPER
conformation to the immune system is difficult. Perhaps the use
of more potent adjuvants along with presentation of the elusive
relevant conformations of the MPER would better elicit MPER-
directed neutralizing antibodies.
Materials and methods
Construction of HBsAg-MPER variants
The synthetic S-gene HBsAg (Berkower et al., 2004) amino
acid 2 to 226 was used as a scaffold to implant the membrane
proximal regions of HIV-1 gp41 at the N-terminus, C-terminus or
the extracellular loop of the HBsAg. S1 gene was PCR amplified
Table 2
Oligonucleotides used for generating HBsAg-MPER constructs
Primer name Primer sequence
SAg forward 5′ GGAGCTCGTCGA CAGCAA 3′
SAg reverse 5′ GC TCT AGA CCC GAT GTA
CAC CCA 3′
MPER forward 5′ GC TCT AGA AAC GAG CAG
GAG CTG CTG 3′
MPER reverse 5′ CGC GGATCC TCA CCC CTT
GAT GTA CCA CAG CCA CTT 3′
MPER-Foldon Rev 5′ CGC GGATCC TCA ATG GTG
ATG GTG ATG GTG GGG 3′
C-heptad-MPER
forward
5′ GC TCT AGA GCC GTG GAG
CGG TAC CTG 3′
MPER-Tm5 reverse 5′ CTCGGATCCTCAAATCATGA
TGAAAATCTTGAT 3′
MPER-Tm10 reverse 5′ CTCGGATCCTCACACCAGGC
CACCAACAAT 3′
MPER-Tm15 reverse 5′ CTCGGATCCTCACACCAGCC
TCAGGCCCAC 3′
MPER-Tm23-C9 reverse 5′ CTCGGATCCTCAGGCGGGCGC 3′
AgeI forward 5′ CCCTGCAAGACCTGCACC ACCACC
GGTCAGGGCAACTCCAAGTTCCCC 3′
AgeI reverse 5′ GGGGAACTTG GAGTTGCCCT
GACCGGTGGT GGTGCAGGTC TTGCAGGG 3′
MPER AgeI forward 5′ GGC ACC GGT AAC GAG CAG
GAG CTG CTG 3′
MPER AgeI reverse 5′ GGC ACC GGT CCC CTT GAT GTA
CCA CAG CCA CTT 3′
MPERSAG forward 5′ AGC GAATTC AAC GAG CAG
GAG CTG CTG 3′
MPER SAG reverse 5′ CGC GGATCC TCA CCC GAT
GTA CAC CCA 3′
SAGMPER RI forward 5′ CAG GAA GCC GGA GGT GATGAA
CCC CTT GAT GTA CCA CAG CCA CTT 3′
SAG MPER RI reverse 5′ AAG TGG CTG TGG TAC ATC AAG
GGG TTC ATC ACC TCC GGC TTC CTG 3′
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CGTCGACAGCAA 3′ and reverse primer 5′ GCTCTA GAC-
CCGATGTAGACCCA 3′ to introduce SalI site at the 5′ and
XbaI site at the 3′ end of the gene. The PCR-amplified pro-
duct was cloned in to pCMV/R vector at the SalI and XbaI
sites. Variants of gp41 sequences containing the MPER were
PCR amplified using codon-optimized HIV-1 YU2 gp160 or
JRFLgp160 constructs as the template. Primer pairs used are
listed in Table 2. The MPER was positioned at the C-terminus of
S1 gene (C-MPER) and at the N-terminus after the 2nd and 3rd
amino acids (E and F, respectively), of the HBsAg S1 sequence
(N-MPER). An AgeI site was created in the extracellular loop of
the S1 gene by replacing amino acids P126 and A127 with T and
G substitutions. Following the G residue, the MPER codons
(with a 3-amino-acid linker GTG at the C-terminus of the
MPER codons) were cloned at the AgeI site to place it in the
extracellular loop of S1 sequences (ECL-MPER). The se-
cond sets of constructs were generated to introduce different
lengths of HIV-1 transmembrane region after the lysine 683
of the MPER, 1IFIMI5 for C-MPER−5, 1IFIMIVGGLV10 for
C-MPER−10, 1IFIMIVGGLVGLRLV15 for C-MPER−15
and 1IFIMIVGGLVGLRLVFSIETGG22TETSQVAPA-C9 tag
for C-MPER−22-C9 in order to further stabilize and orient the
4E10 epitope. The final set of constructswas generatedwithHIV-1
gp41 region, C-heptad and or the MPER at the C-terminus of
HBsAg. Between the HBsAg and the gp41 regions, 2 amino
acids S and R were introduced and following K at residue 683,
a glycine was placed immediately before the stop codon. The
T4 fibritin trimerization domain, foldon, was also introduced in
two of the constructs to see the effect of trimerization on re-
combinant HBsAg particle production and recognition of 2F5 and
4E10.
Transient transfections, particle production and analysis
All the constructs were transfected in HEK293T cells. One
day prior to transfection, 8 million HEK 293T cells in DMEM,
10% FBS, 1% penicillin–streptomycin (pen–strep) were seeded
in a 150-mm tissue culture dish. The cells were transfected with
the plasmids encoding recombinant HBsAg-MPER and MPER
variants or wild-type HBsAg using Fugene6 (Roche) at a ratio
of DNA:Fugene6 1:3 and 10 μg total DNA plate. Four days
after transfection, cells and supernatant were collected. Super-
natant was concentrated using Centricon Plus-80 100-kDa Bio-
max membrane (Millipore, Billerica, MA) to 25 ml. The cells
were lysed by resuspending it in 10 ml of 1× PBS and soni-
cation for 1 min at 20 Hz every 10 s using a probe sonicator and
the cell lysate was clarified by centrifugation at 15,000 rpm in
an Eppendorf centrifuge for 15 min. Cell lysates were loaded
on a 20% sucrose cushion (20% sucrose in PBS) and
centrifuged at 23,000 rpm for 16 h (Surespin rotor, Sorvall).
The partially purified VLPs were resuspended in PBS and
analyzed by ELISA or Western blotting. To further purify the
VLPs, the particles were loaded onto a 10–40% (wt/wt) CsCl
step gradient (in PBS) and centrifuged at 22 h at 36,000 rpm
(TV-860 rotor; Sorvall), and 500 μl fractions were taken from
the bottom of the tube. ELISA identified the fractions contain-ing VLPs. The positive fractions were, desalted, concentrated,
washed with PBS using Amicon YM-100 filter (Millipore).
EM analysis of the particles
The HEK293 cells transfected with C-terminus HBsAG-
MPER DNAwere collected 24 h after transfection and washed
with PBS. Approximately 3×106 cells were fixed in 2% para-
formaldehyde–2% glutaraldehyde in 0.10 M cacodylate buffer.
Thin sections were negatively stained with 2% methylamine
tungstate and analyzed by electron microscopy at a magnifica-
tion of 100,000×. For cell-free particles, the fractions from the
CsCl gradient were selected by optical density and the particles
contained in those fractions were negatively stained with 2%
methylamine tungstate and analyzed by electron microscopy.
Recombinant baculovirus particle production
The HBsAg-MPER sequence was PCR amplified from
pCMV/R HBsAg-MPER construct and ligated into the pFastbac
plasmid between the SalI and SpeI restriction sites. The pFastbac
sAg-MPER plasmid was transformed into competent cells con-
taining full-length bacmid DNA (Invitrogen), to generate re-
combinant bacmid. Two positive bacmids were sent to ATG
82 S. Phogat et al. / Virology 373 (2008) 72–84Laboratories, Inc., in Eden Prairie, MN, for titer and production
of recombinant baculovirus in Sf9 cells. For particle production,
the Hi5 or Sf8 cells were infected at a multiplicity of infection of
four and the cell pellets were harvested at about 48 h following
infection. Cells were lysed by sonication and the lysate was
layered onto sucrose gradients. After sedimentation for 2 h at
27,000 rpm in an SW28 rotor, fractions were collected from the
bottom. Each fraction was assayed for MPER content, using
monoclonal antibody 2F5. Particles were further purified either
by CsCl gradient centrifugation for immunogenicity as des-
cribed above or on a Macro-prep methyl HIC column (from Bio
Rad) for SDS gel analysis. For purification by the hydrophobic
methyl Macro-prep method, particles in the pooled sucrose
fractions were suspended in 0.01 M sodium phosphate buffer,
pH 6.8 with 0.6 M ammonium sulfate and 0.05% CHAPSO
(Anagrade), washed in the same buffer and eluted with 0.2 M
ammonium sulfate.
ELISA analysis of the HBsAg-MPER particles
To determine the presence of HBsAg, HBsAg-MPER and
MPER variants VLPs in the preparations, ELISAs were per-
formed as follows. For direct ELISA, the particles were ad-
sorbed onto a high-protein-binding microwell plate (Corning)
for 2 h, then incubated with blocking buffer (bb; PBS with 2%
dry milk). After one wash with PBS/0.2% Tween-20, anti-
HBsAg antibody NE3 or NF5 (Aldevron) was added to each
well in serial dilution and incubated at 37 °C for 1 h. After three
washes with PBS/0.2% Tween-20, a secondary anti-mouse–
IgG–HRP antibody (Sigma) was added in washing buffer at a
1:5000 dilution for 1 h at 37 °C. Following three washes, the
ELISAs were developed with 100 μl TMB Peroxidase substrate
(KPL). The reaction was stopped by adding 100 μl 1 M HCl to
each well. The optical density at 450 nm was read on a
microplate reader (Molecular Devices).
For sandwich ELISA, 500 ng of the HBsAg-specific mouse
monoclonal antibody NE3 (Aldevron) was adsorbed onto each
well overnight at 4 °C. The next day, following incubation of
bb, the particles were resuspended in PBS and 100 μl of the
suspension was added to each well and incubated 37 °C for 2 h.
After one wash with PBS/0.2% Tween-20, either the antibody
2F5 or 4E10 (kindly provided by H. Katinger) or HIVIgG (NIH
AIDS Reagent Repository Program) was added to each well as a
serial dilution and incubated at 37 °C for 1 h. After three washes
with PBS/0.2% Tween-20, a secondary anti-human–IgG–HRP
antibody (Jackson Immuno Research laboratories) was added in
washing buffer at a 1:5000 dilution for 1 h at 37 °C. Following
three washes, the ELISAs were developed as described above.
For competition ELISA, all the steps similar to sandwich
ELISA were performed except that the peptide NEQELLE-
LDKWASLWN was mixed along with 2F5 diluted and incu-
bated at 37 °C for 1 h. To determine the effect of lipid on
antibody binding, the baculovirus-expressed C-terminus MPER
particles were treated with high and low pH and in PBS con-
taining 1% CHAPSO and then diafiltered to remove the lipids
and concentrate the particles. To a portion of the delipidated
particles, the lipids DOPC:DOPS (7:3) (Avanti Polar lipids, Inc.)were added, the samples was dialyzed against PBS and all
particle preparations were analyzed by sandwich ELISA.
Inoculations
BalB/c mice were inoculated by the intramuscular route at
intervals of 3 weeks with 5 μg of HBsAg or HBsAg-MPER par-
ticles in the presence of alum or 50 μg of HBsAg, HBsAg-MPER,
HBsAg-MPER+15 DNA followed by HBsAg or HBsAg-MPER
particle/alum boost. Animals were inoculated up to a total of five
times. Sera was collected 7–10 days after each inoculation and
analyzed either by ELISA, cell surface staining by FACS or in
selected instances by a neutralization assay.
For the prime:boost immunization strategy, rabbits were im-
munized by two priming immunizations at weeks 0 and 4,
followed by two boosting immunizations at weeks 8 and 12.
The dose of inoculation of the ADA Env-PLs was approxi-
mately 20 to 30 μg of envelope glycoproteins as estimated by
SDS gels using a defined volume of Env-PL bead suspension.
Inoculation was by the intradermal route and CpG plus alum
was used as adjuvant for all the immunogens.
Fluorescence-activated cell sorting (FACS) staining at the cell
surface
FACS staining was performed as previously described (Koch
et al., 2003; Pancera and Wyatt, 2005). Forty-eight hours fol-
lowing transfection, the cells were harvested and washed in
FACS buffer (PBS, 5% fetal bovine serum, 0.02% azide) and
stained with sera from mice immunized with HBsAg or HBsAg-
MPER. The polyclonal antibodies were washed in FACS buffer
and anti-mouse-FITC (SIGMA) at a 1:200 dilution was added
for 30 min and then washed to remove unbound secondary
antibody. The stained cells were analyzed by FACS on a Beck-
man Coulter Calibur Instrument.
Virus neutralization assay
Single-round virus neutralization was performed as described
earlier (Li et al., 2006; Shu et al., 2007). In brief, HIV-1 was
pseudotyped with selected envelope glycoproteins by the co-
transfection of an env expressor and viral genomic DNA with a
deletion of Env into 293T cells. The MN Env plasmid was
provided byDavidMontefiori, MW965was obtained for the NIH
AIDSResearch andRegent Program. Following the production of
pseudotyped virus, a luciferase-based neutralization assay was
performed as previously described. Briefly, TZM-bl cells ex-
pressingCD4,CXCR4, andCCR5were used for HIV-1 infection.
These target cells contain Tat-responsive reporter genes for firefly
luciferase and the Escherichia coli β-galactosidase gene under
the regulatory control of the HIV-1 long terminal repeat. The level
of HIV-1 infection was quantified by measuring relative light
units (RLU) of luminescence, which is directly proportional to the
amount of virus input. The assayswere performed using a 96-well
microtiter plate format with 10,000 TZM-bl cells per well. For
neutralization assays, each pseudotyped virus stock was diluted to
a level that produced approximately 100,000 to 500,000 RLU.
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sample was derived by calculating the reduction in RLUs in the
test wells compared to the RLUs in the wells containing pre-
immune serum from the corresponding animal. To control for
nonspecific neutralization in protein-immunized rabbits, sera
from two animals immunizedwith BSAwere analyzed. All serum
samples were also assayed for neutralizing activity against a
pseudovirus expressing the amphotropic murine leukemia virus
envelope to test for non-HIV-1-specific plasma effects (Mascola
et al., 2002). To obtain IC50 and IC80 data, fivefold serial dilution
of immune sera were incubated with viruses before infection of
target cells. Antiserum dose–response curves were fit with a
nonlinear function, and the IC50 and IC80 for the corresponding
virus were calculated by a least squares regression analysis.
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